Please assess the completion status of the following clinical trial:

Trial Title: Chemotherapy Plus Surgery in Treating Women With Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Unilateral carcinoma of the breast that has not been previously treated with standard therapies~* Tumor greater than 2 cm in its maximum diameter as assessed by mammography, except:~  * No locally advanced disease, i.e., no tumor with direct extension to the chest wall or skin~ * No metastatic disease~* Hormone receptor status:~  * Not specified~PATIENT CHARACTERISTICS:~Age:~* 18 to 70~Sex:~* Female~Menopausal status:~* Not specified~Performance status:~* Karnofsky 80-100%~Hematopoietic:~* Granulocyte count at least 2,000/mm\^3~* Platelet count at least 150,000/mm\^3~Hepatic:~* Bilirubin within upper limits of normal (ULN)~* Alkaline phosphatase no greater than 1.5 times ULN~* AST no greater than 1.5 times ULN~* No chronic active hepatitis~Renal:~* Creatinine within ULN~Cardiovascular:~* No prior atrial or ventricular arrhythmias~* No history of congestive heart failure~* No myocardial infarction within the past 6 months~* No uncontrolled hypertension~Neurologic:~* No pre-existing motor or sensory neuropathy greater than grade 1~Other:~* Not pregnant or nursing~* Fertile patients must use effective contraception~* No active infection~* No history of second malignancy except adequately treated basal cell skin cancer or carcinoma in situ of the cervix~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* No prior biologic therapy~Chemotherapy:~* No prior chemotherapy~Endocrine therapy:~* No prior endocrine therapy~Radiotherapy:~* No prior radiotherapy~Surgery:~* No prior surgery~* No prior surgical biopsy of breast nodule

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).